Psilocybin for Treatment-Resistant Depression

Status Completed

Clinical Trial Summary

The purpose of this study is to see if psilocybin, an investigational drug, is safe and well tolerated. Researchers also want to know if psilocybin can improve symptoms of depression. This study will see if psilocybin is safe and well tolerated by tracking changes in suicidal thoughts and behaviour, monitoring if any participants choose to stop participating in the study, and measuring any serious side effects, as well as how long they take to resolve. This study will also see if depression symptoms improve (or worsen) after psilocybin is administered. Additional information about participants' depressive symptoms and side effects will also be measured during the study.

Clinical Trial Description

This randomized clinical trial will assess the feasibility, safety, and efficacy of single and repeat doses of psilocybin at point-of-care in persons with treatment-resistant depression as part of major depressive disorder or bipolar II disorder. The primary objective is to evaluate the feasibility of psilocybin in adults with treatment-resistant depression. The secondary objectives are to assess the efficacy and tolerability of psilocybin at point-of-care. ;

Study Design

Related Conditions & MeSH terms

Depression
Depressive Disorder
Depressive Disorder, Treatment-Resistant
Treatment Resistant Depression

Clinical Trial Details

NCT number	NCT05029466
Study type	Interventional
Source	Brain and Cognition Discovery Foundation
Contact
Status	Completed
Phase	Phase 2
Start date	November 19, 2021
Completion date	July 22, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04124341` - PCS in Severe Treatment Resistant Depression	N/A
Recruiting	`NCT03887715` - A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression	N/A
Completed	`NCT04727229` - Stellate Ganglion Block for Major Depressive Disorder.	Phase 4
Completed	`NCT04634669` - Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)	Phase 2
Withdrawn	`NCT03175887` - Investigational TMS Treatment for Depression	N/A
Completed	`NCT03134066` - Neurocognitive Features of Patients With Treatment-Resistant Depression
Active, not recruiting	`NCT01984710` - Deep Brain Stimulation for Treatment Resistant Depression With the Medtronic Activa PC+S	N/A
Completed	`NCT01935115` - Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy	Phase 4
Terminated	`NCT01687478` - A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression	Phase 3
Completed	`NCT00531726` - Berlin Deep Brain Stimulation Depression Study	N/A
Recruiting	`NCT04041479` - Biomarker-guided rTMS for Treatment Resistant Depression	Phase 3
Recruiting	`NCT05870540` - BPL-003 Efficacy and Safety in Treatment Resistant Depression	Phase 2
Recruiting	`NCT04959253` - Psilocybin in Depression Resistant to Standard Treatments	Phase 2
Completed	`NCT04856124` - Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine
Recruiting	`NCT03272698` - ECT With Ketamine Anesthesia vs High Intensity Ketamine With ECT Rescue for Treatment-Resistant Depression	Phase 4
Active, not recruiting	`NCT04451135` - CET- REM (Correlating ECT Response to EEG Markers)	N/A
Recruiting	`NCT05680220` - 40 Hz Light Neurostimulation for Patients With Depression (FELIX)	N/A
Completed	`NCT03288675` - Stepped Care aiTBS 2 Depression Study (Ghent)	N/A
Recruiting	`NCT06138691` - KET-RO Plus RO DBT for Treatment Resistant Depression	Phase 1
Terminated	`NCT02675556` - Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression	Phase 1